A strong 2015 – Continuing high growth in revenues and profit after tax.
A strong year 2015 – Continuing high growth in revenues and profit after tax.
Scandinavian Micro Biodevices (SMB) reports the best financial results ever in 2015 with an increase of 124% in profit after tax.
Sales of our Analyzers under the names QuickVet® and VSpro® continues to grow together with the cartridges developed specific to the platforms.
SMB has since the introduction of the QuickVet® and VSpro® platforms experienced a Compound Annual Growth (CAGR) of 31% in revenues with a significant growth in operational profit.
Our profit after tax in 2015 was 10.3 million DKK, an increase of 123% over previous year.
This positive development has been fueled both by growth in our existing markets, the expansion into new markets and by the introduction of new cartridges to the QuickVet® and VSpro® platform. In 2015 SMB introduced Feline blood typing A, B and AB cartridges. SMB was approved as manufacturer in the important Japanese market, where we expect to initiate sales in 2016 through our appointed distributor.
The company has over the year maintained a strict cost control, which has contributed to the increased profitability.
Throughout 2015 SMB also continued its strategy of investing in new products and platforms within the company’s technology base. On the QuickVet® platform we are developing two new cartridges which will add value to veterinarian clinics and strengthen the customer loyalty to QuickVet®. SMB has made good progress in 2015 developing a new platform within Immunodiagnostic tests which is expected to be introduced onto the market in 2016. This next generation platform will place the company in a strong position for continued growth in the coming years.
SMB has had the honor to be elected Gazelle Company 2015 by the Danish business newspaper Børsen. The Gazelle list cover those companies, out of approx. 38.500 companies, which have had more than 100 % growth in the last 4 years in Denmark. SMB was placed as number 444 on the list or just outside the top 1 %.
Ole Kring, CEO states “We are very satisfied with the development in 2014 because it is the best financial result ever and at the same time we have progressed our technology base and product development significantly which places us in a very strong position for continued growth in the coming years” and continues “2016 is a year of investment for SMB. We plan to invest significantly in entering new markets, product development and production capacity in order to cover the expected cartridge demand for the existing platform and for our new Immunodiagnostic platform. We therefore plan to expand with new employees in Sales and Marketing, Production and Development.
SMB has had the honor to be elected Gazelle Company 2015 by the Danish business newspaper Børsen. Over the last 20 years Børsen been analyzing which companies are high growth companies in Denmark and this year 1.449 companies out of 38.500 companies made the cut to be elected Gazelle Company. Out of the 1.449 company SMB was 444 on the list or in the best 1/3 of the Gazelle companies. Comparing with all companies evaluated this year, our ranking as 444 places SMB just outside the top 1% for of the 38.500 companies.
SMB is very proud of the achievement, as it exemplifies the core of the growth journey that SMB is on and is a tribute to the fantastic team of employees at SMB. It is their achievement that SMB this year is a company who in the last 4 accounting years have had continuous growth in turnover / gross result and who has doubled this in the 4 year period.
European Animal Health Investment Forum
February 10-11, 2016
SMB is proud to announce that we have been selected to be a showcasing emerging company for the first and only European Animal Health Investment Forum, taking place February 10-11, 2016 at the Royal Garden Hotel in London, UK. We are one of the twelve selected companies who will be presenting our innovations to an audience of financial investors, diagnostic companies and big pharma representatives.
The event will have 100+ influencers and decision-makers from the animal health industry including companies such as Zoetis, MSD Animal Health, Merial, Boehringer Ingelheim, Bayer Animal Health as we discuss the big picture of animal health and learn about the most innovative and new emerging companies.
Online information on the event at www.animalhealthevent.com.